Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 11/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29396583 | 0.98 | QDPR (0.46) | QDPRTLR9TLR7TLR8CHRNB2 | |
| SCHEMBL22609014 | 0.91 | CHRNB2 (0.48) | QDPRCHRNB2CHRNA4 | |
| SCHEMBL29399373 | 0.87 | QDPR (0.47) | QDPRTLR9TLR7TLR8CHRNB2 | |
| Hydrochloric Acid SCHEMBL29396594 | 0.86 | KDM4E (0.47) | QDPRTLR9TLR7TLR8CHRNB2 | |
| Hydrochloric Acid SCHEMBL29625119 | 0.84 | KDM4E (0.46) | QDPRTLR9TLR7TLR8CHRNB2 | |
| SCHEMBL23122792 | 0.80 | QDPR (0.49) | QDPRTLR9TLR7TLR8 | |
| SCHEMBL22609013 | 0.78 | CHRNB2 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL30292959 | 0.77 | TLR9 (0.68) | TLR9TLR7TLR8 | |
| SCHEMBL31110437 | 0.74 | QDPR (0.47) | QDPRTLR9TLR7TLR8HTR2C | |
| SCHEMBL5414860 | 0.74 | IP6K1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022148196-A1 | MULTIKINASE INHIBITOR AND USE THEREOF | 苏州安睿药业有限公司 | 2022-07-14 | — | — | WO | disclosed |